Beijing, China / Frankfurt, Germany, November 5, 2025 — The world's leading pharmaceutical event, CPHI Worldwide 2025, has successfully concluded at Messe Frankfurt. Gan & Lee Pharmaceuticals. (hereinafter referred to as Gan & Lee, stock code: 603087.SH) once again stepped onto the global stage, showcasing its latest innovations and achievements alongside more than 2,400 exhibitors and 62,000 pharmaceutical professionals from 166 countries. Centered around the theme"Precision · Innovation · Global Accessibility," Gan & Lee's booth integrates the aesthetic charm of traditional Chinese ink wash landscape art, creating a space that seamlessly blends scientific communication with visual artistry.

During the exhibition, the Gan & Lee team spotlighted our cutting-edge innovations — the once-weekly insulin formulation GZR4 injection and the biweekly GLP-1RA formulation bofanglutide (GZR18) injection — presenting the latest clinical data to visitors, professionals, and partners. The data demonstrated our solid scientific foundation and deep commitment to metabolic disease therapy.

In response to diverse market needs, Gan & Lee also introduced a localized collaboration model tailored for emerging markets and reached preliminary cooperation agreements with several potential global partners, laying a solid foundation for the company's expanding international strategy.

Since initiating our globalization journey in 2005, Gan & Lee’s products have achieved commercialization in 20 countries, continuously improving the accessibility of diabetes treatments worldwide.

At the exhibition, Dr. Zhi Li, Executive Vice President and Chief Business Officer (CBO) of Gan & Lee, remarked: "Our booth not only serves as a window to our products but also a reflection of Gan & Lee's spirit. The towering mountains symbolize our relentless pursuit of scientific excellence, while the flowing water represents our commitment to bringing innovative therapies to patients around the world. Looking ahead, we will continue to drive precision innovation guided by clinical needs, bolster R&D investment, and deepen global partnerships — so that our high-quality medical solutions may nourish lives like gentle rain upon distant mountains."

About Gan & Lee

Gan & Lee Pharmaceuticals developed the first Chinese domestic insulin analog. Currently, Gan & Lee has six core insulin products, including five insulin analog varieties: long-acting glargine injection (Basalin^®), fast-acting lispro injection (Prandilin™), fast-acting aspart injection (Rapilin^®), mixed protamine zinc lispro injection (25R) (Prandilin™25), aspart 30 injection (Rapilin^®30), and one human insulin injection - mixed protamine human insulin injection (30R) (Similin^®30). The company has two approved medical devices in China, namely reusable insulin injection pen (GanleePen), and disposable pen needle (GanleeFine^®).

In China's 2024 National Insulin-Specific Centralized Procurement, Gan & Lee Pharmaceuticals ranked  first among all selected companies in terms of procurement demand for insulin analogs. The company is also making strides in international markets, with the disposable pen needle (GanleeFine^®) approved by the US Food and Drug Administration (FDA) in 2020 and received GMP inspection approval from the European Medicines Agency (EMA) in 2024. These achievements significantly boost Gan & Lee’s competitiveness in both international and domestic markets.

In the future, Gan & Lee will strive for comprehensive coverage in diabetes treatment. Moving forward with its mission to become a world-class pharmaceutical company, Gan & Lee will also actively develop new chemical entities and biological drugs, focusing on treatments for metabolic diseases, cardiovascular diseases, and other therapeutic areas.